Recon: Merck to buy Acceleron for $11.5B; AstraZeneca vaccine shows 74% efficacy in US trial

Recon

ReconMichael Mezher

Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy